Lannett intros generic Concerta
Lannett announced that it has introduced its generic Concerta ( hydrochloride extended-release tablets). The generic of Janssen's branded product will be available in dosage strengths of 18 mg, 27 mg, 36 mg and 54 mg.
The product is the generic of Janssen’s Concerta.
Methylphenidate hydrochloride ER tablets had a market value of approximately $1.4 billion for the 12 months ended February 2019, according to IQVIA, although actual generic market values are expected to be lower.
"Our launch of AB-rated bethylphenidate is ahead of schedule," Lannett CEO Tim Crew said. "Of the more than 20 new products we have launched over the last 18 months, we expect the AB-rated methylphenidate product to be one of our top contributors. Since Jan. 1 of this year, we have now launched six products and expect to launch several more products over the coming months."
Lannett's strategic alliance partner, Andor Pharmaceuticals, recently received approval from the Food and Drug Administration for the product and Lannett entered into a licensing agreement with Andor for the generic. Under the agreement, Lannett is providing sales, marketing and distribution support of Andor's methylphenidate ER product and receives a percentage of the net profits.
The product is the generic of Janssen’s Concerta.
Methylphenidate hydrochloride ER tablets had a market value of approximately $1.4 billion for the 12 months ended February 2019, according to IQVIA, although actual generic market values are expected to be lower.
"Our launch of AB-rated bethylphenidate is ahead of schedule," Lannett CEO Tim Crew said. "Of the more than 20 new products we have launched over the last 18 months, we expect the AB-rated methylphenidate product to be one of our top contributors. Since Jan. 1 of this year, we have now launched six products and expect to launch several more products over the coming months."
Lannett's strategic alliance partner, Andor Pharmaceuticals, recently received approval from the Food and Drug Administration for the product and Lannett entered into a licensing agreement with Andor for the generic. Under the agreement, Lannett is providing sales, marketing and distribution support of Andor's methylphenidate ER product and receives a percentage of the net profits.